Men, baby boomers, and postgraduate-degree holders were among those most likely to say they wouldn’t choose medication over ...

Speakers from across the care continuum will discuss legislative updates, glucagon-like peptide-1 (GLP-1) use for weight management, and more at this year’s AMCP Nexus.

The novel GLP-1 receptor agonists will likely reduce the need for CABG and improve surgical outcomes, several argue.

Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...

Skye Bioscience (NASDAQ: SKYE) is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space.

Background Clinical studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1 RA) can have beneficial effects ...

The surge in popularity of drugs like Ozempic, driven in part by its weight loss benefits, is contributing to a record-high ...

On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 ...

Research highlights how GLP-1 receptor agonists may improve brain health by targeting the neurovascular unit, linking ...

Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...